Tramadol, an opioid analgesic, is not routinely included in standard drug screening panels. Consequently, its presence in a system will not be detected unless a specific assay for tramadol or its metabolites is requested. The use of expanded or specialized testing is necessary to identify tramadol consumption.
The necessity for targeted testing arises from tramadol’s unique metabolic pathway and its potential for misuse. While offering pain relief, tramadol carries a risk of dependence and abuse. Therefore, specific detection methods are crucial in scenarios such as workplace drug monitoring, forensic toxicology, and clinical settings where patient compliance is paramount.
